BusinessXOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital HyperinsulinismBy Nasdaq OMXOct 19, 2016, 1:01 PM UTC
BusinessPetLife Pharmaceuticals Expands Cell Line Study with InnoVision in Preparation for FDA/CVM Registration SubmissionBy Nasdaq OMXOct 13, 2016, 12:02 PM UTC
BusinessSummit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXSep 27, 2016, 11:00 AM UTC
BusinessFate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell TransplantationBy Nasdaq OMXSep 26, 2016, 12:00 PM UTC
BusinessSummit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXSep 26, 2016, 11:00 AM UTC
BusinessAkari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal HemoglobinuriaBy Nasdaq OMXSep 12, 2016, 11:15 AM UTC
BusinessPetLife Pharmaceuticals Hires InnoVision Therapeutics in Preparation of Vitalzul™ FDA SubmissionBy Nasdaq OMXAug 25, 2016, 12:43 PM UTC
